Previous 10 | Next 10 |
The markets have been performing very well in 2019 with the Dow Jones, the Nasdaq, and the S&P 500 all up more than 20% since the beginning of the year. That's great news for investors who are already holding stocks, but for those looking to get into the market for the first time, it means c...
The past year has been a painful one for shareholders in Innoviva Inc. ( INVA ), with shares down about 27% in that time. I think now is a good time to buy the shares, and I'll go through my reasoning below by looking at the financial history here, paying particular attention to the valuation ...
Innoviva (NASDAQ: INVA ): Q3 GAAP EPS of $0.36 beats by $0.03 . More news on: Innoviva, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Total net revenue increased by 7% to $65.8 million in the third quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 15% to $57.6 million in the third quarter of 2019, compared to the same quarter in 2018. Innoviva, Inc. (NASDAQ: INVA) (t...
GlaxoSmithKline (NYSE: GSK ) and Innoviva (NASDAQ: INVA ) announce the filing of a supplemental new drug application to the FDA for an additional indication for the use of Trelegy Ellipta for asthma in adults. More news on: GlaxoSmithKline plc, Innoviva, Inc., Healthcare stocks n...
GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone fur...
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Combining 3 valuation ratios, biotechnology looks undervalued by about 40% relative...
Innoviva ( INVA -11.5% ) is down on below-average volume after posting less-than-expected Q2 results after the close yesterday. Highlights: More news on: Innoviva, Inc., Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more ...
Innoviva (NASDAQ: INVA ): Q2 GAAP EPS of $0.34 misses by $0.09 . More news on: Innoviva, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Total net revenue decreased by 4% to $64.1 million in the second quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased slightly to $56.5 million in the second quarter of 2019, compared to the same quarter in 2018. Innoviva, Inc. (NASDAQ:INVA)...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...